The two companies cooperate to promote the broader integration of AI and innovative molecular research and development

In the biomedical innovation boom, the research and development of innovative small molecule drugs is still the mainstream, and with the blessing of new technologies, the small molecule drug market will usher in new opportunities and challenges
.
Among them, the application of AI technology is of great significance for the research and development of small molecule drugs
.
The author was informed that Nhwa Pharmaceutical has recently reached a strategic cooperation agreement with Shenshi Technology, and the two parties will jointly promote Nhwa Pharmaceutical's research and development of small molecule innovative drugs in the central nervous system
.
At the same time, the two parties will further explore the advantages of cooperation, combine AI technology and innovative molecular research and development more widely, and accelerate and expand the research and development process and innovation dimension of drugs in the central nervous system
.
Shenshi Technology said that this cooperation will deeply integrate the computing paradigm based on 'AI + molecular simulation' into the actual cooperative research and development project, and jointly create a research and development model of 'computational design-experimental verification', looking forward to accelerating new drugs in the central nervous system.
Development brings more new results
.
It is understood that the Hermite drug design platform mentioned in the cooperation between the two parties is the preclinical computer aided drug design (CADD) platform rooted in cloud computing launched by Shenshi Technology
.
The platform can accurately predict protein structure and conformational changes, and efficiently evaluate the binding free energy of proteins and ligands with chemical precision, which will greatly improve protein structure prediction, drug target discovery, new drug molecular design, and experimental design and other new drug research and development work efficiency, thereby promoting the overall reform and upgrading of the pharmaceutical industry
.
Artificial intelligence (AI) and biocomputing technologies are empowering research in the field of life sciences and accelerating the development of new drugs
.
The industry said that the application of AI technology in the field of biopharmaceuticals is conducive to creating an interdisciplinary drug research and development platform and is conducive to source innovation
.
Nowadays, as the requirements for the drug approval process are becoming more and more stringent, the requirements for drug side effects are getting higher and higher, and the speed of new drug development is also affected to a certain extent
.
The application of AI technology may reduce research and development time and cost, making the field of innovative drugs more promising
.
It is reported that more and more investors are now paying attention to the field of AI drug research and development
.
According to relevant statistics, there will be 56 investment activities in the field of AI drug research and development in 2021, including 13 investment activities of hundreds of millions of dollars
.
As on December 16, 2021, antibody design company Nabla Bio raised $11 million in seed funding
.
The company intends to use the funding to accelerate development of an AI-first protein design platform that enables rapid end-to-end engineering of next-generation antibody therapeutics
.
On August 9, 2021, Wuhan Zhihua Technology announced the completion of a round A+ financing of nearly 15 million US dollars, led by Source Code Capital, and followed by Sequoia China, Fengrui Capital and Huafang Capital.
This financing is mainly used for AI automation Synthetic platform construction and improvement and professional marketing
.
On April 26, 2021, Suozhi Bio, an AI-driven new biopharmaceutical company, announced the completion of an angel round of financing of RMB 50 million
.
Sozhi Bio’s angel round of financing was led by Baitu Biotechnology and followed by Via Bio
.
As strategic investors, Baitu Biotechnology and Via Bio will provide support to Suozhi in terms of AI technology, computing power, underlying multi-dimensional data, protein structure and new drug research and development
.
On April 12, 2021, Wangshi Wisdom announced that it has completed the B+ and B rounds of financing, with a total financing of 100 million US dollars
.
The financing will be mainly used to further attract the world's top talents, consolidate the industrialization results of Wangshi AI platform, speed up the iteration speed of Wangshi AI technology innovation, and improve the empowerment efficiency
.
Drug development is a complex process, and artificial intelligence (AI)-based predictive models are emerging as a revolutionary solution to increase the efficiency and speed of drug design and development, especially by optimizing therapeutic targets and drug candidates.
select
.
Artificial intelligence (AI) enables a more personalized approach known as "precision medicine" by providing a means to capture the value of data related to diagnosis, patient characteristics, drug candidate properties, and prediction of treatment response More suitable for the treatment of individual patient characteristics
.
With the continuous progress of artificial intelligence (AI) technology, it will have a broader market application in the field of drug research and development in the future
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.